Why Rapid Medical’s DISTALS data could reshape treatment expectations in smaller stroke vessels
Distal stroke has long lacked device options. Rapid Medical’s TIGERTRIEVER 13 data now tests whether small-vessel thrombectomy can scale.
Can Medtronic’s $550m Scientia Vascular deal improve catheter and guidewire technology for stroke treatment?
Medtronic plans to acquire Scientia Vascular for $550M. Explore what the deal changes for stroke intervention devices and neurovascular procedure access.
Can CereVasc’s eShunt system change the future of idiopathic intracranial hypertension treatment?
CereVasc’s eShunt system shows three-year outcomes in idiopathic intracranial hypertension. Discover what this means for future brain pressure treatments.
Rapid Medical’s DISTALS trial signals a structural shift in how medium vessel stroke may finally be treated
Rapid Medical disclosed late-breaking results from its DISTALS randomized controlled trial showing that the TIGERTRIEVER 13 thrombectomy device achieved significantly higher tissue reperfusion without symptomatic intracranial hemorrhage compared with medical management in medium vessel occlusion stroke. The data were presented at the 2026 International Stroke Conference and form the basis for a planned United States […]
Could CereVasc’s eShunt replace VP shunts in post-aneurysmal hydrocephalus treatment?
CereVasc completes ETCHES trial enrollment for its eShunt device in post-SAH hydrocephalus. Learn what this means for future neurosurgical care.